The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer. Fujirebio also grants
US-based ZymoGenetics has reduced its workforce by approximately 32%, or 161 employees, as part of a corporate restructuring. ZymoGenetics said that it is reorganizing its operations to focus
US-based Medicis and French pharmaceutical company Ipsen have reported that the FDA has approved the biologics license application for Dysport, an acetylcholine release inhibitor and a neuromuscular blocking
ImmunoCellular Therapeutics, a biotechnology company, has received a new US patent relating to the company’s monoclonal antibody therapeutics. The patent covers the use of ImmunoCellular Therapeutics’s (IMUC’s) antibodies
UK-based biopharmaceutical company Oxford BioMedica has reported that, as part of Sanofi-Aventis’s reprioritization of its product portfolio, Oxford BioMedica has regained worldwide rights to TroVax, its therapeutic cancer
Swiss biopharmaceutical company Basilea Pharmaceutica has received approval from the Dutch Medicines Evaluation Board for Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema
Milestone Scientific, a developer of advanced injection technologies, has granted China National Medicines Corporation, doing business as Sinopharm, exclusive distribution and marketing rights of the STA Single Tooth
Lipoxen, a biopharmaceutical company, and Cambridge Biostability, or CBL, a developer of temperature-stable vaccines and biopharmaceuticals, have achieved positive preclinical results for the delivery of an enhanced influenza
Phase Forward, a provider of integrated data management solutions for clinical trials and drug safety, has reported a net income of $4.08m, or $0.09 per share, for the
Wyeth has reported a net income of $1.198 billion, or $0.89 per diluted share, for the first quarter of 2009, compared to $1.196 billion, or $0.89 per diluted
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.